Biologyarticle2026-09-04

Beyond in silico prediction: multi-omics to identify a pathogenic deep intronic HNRNPK variant in Au-Kline syndrome

Open access0 citations

Abstract

Abstract Pathogenic variants in HNRNPK are associated with autosomal dominant Au-Kline syndrome (AKS, Au-Kline-Okamoto syndrome, OMIM #616580). This syndrome is characterized by developmental delay and intellectual disability, hypotonia, and distinctive facial features. Despite the use of whole-genome sequencing (WGS) as a powerful diagnostic tool, we nearly dismissed a novel intronic variant (NM_031263.4(HNRNPK):c.214-55 T > A) affecting HNRNPK splicing and function. Although commonly used bioinformatic splice prediction tools, including SpliceAI and PDIVAS, yielded inconclusive results, Face2Gene analysis indicated a high phenotypic similarity to AKS. Characteristic facial features described by Choufani et al. [1] supported the clinical diagnosis of AKS. Subsequent functional studies demonstrated aberrant splicing with intron retention, and DNA methylation profiling revealed a positive HNRNPK -specific episignature. These insights and the de novo status support an evaluation as likely pathogenic. This case report supports the relevance of facial analysis and comprehensive variant validation strategies, particularly for deep intronic variants with ambiguous in silico splicing predictions.

// Source

View paper (DOI)Open access versionOpenAlexJournal of Human GeneticsPublished 2026-09-04

Authors: Z. Kowalzyk, J. Porrmann, P.Y.B. Au, S. Choufani, Rosanna Weksberg, K. Hackmann, A. Kübler, A. Kögler, N.S. LEWIS, A. Köhler, J. Wagner, M. Bermudez, C. Hubner, J. Schallner, R. Jauss, C. Vogelberg, B. Mayer, N. Di Donato, E Schröck, D. Le Duc, A. Jahn

Institutions: University of Toronto, University of Calgary, Leipzig University, University Hospital Carl Gustav Carus, German Cancer Research Center, Hospital for Sick Children, SickKids Foundation, Alberta Children's Hospital, National Center for Tumor Diseases, Helmholtz-Zentrum Dresden-Rossendorf, Nationales Centrum für Tumorerkrankungen Dresden